A new study reports that reovirus has the potential to treat certain lung cancer patients, when the reovirus is combined with two other substances known as paclitaxel and carboplatin.

The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC.

The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

The researchers concluded that reovirus can be successfully delivered specifically to colorectal liver metastases following intravenous administration as a monotherapy and that pre-operative treatment was safe.

Oncolytics Biotech Inc announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin.

There may be new hope for colorectal cancer patients who fail on first-line drug combinations harnessed against tumors that harbor a mutation in the kras oncogene.

Researchers at Weill Cornell Medical Center in New York have demonstrated that a reovirus therapy called REOLYSIN works synergistically with gemcitabine and may be worth further investigation.